The old idiom "blink, and you'll miss it" might be the best descriptor of the historic volatility we've witnessed on Wall ...

PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors ...

Photo Alamy President Trump revealed a new plan to impose tariffs on foreign pharmaceuticals Tuesday night while speaking at the National Republican Congressional Committee Dinner. He stated, “We’re ...

UBS reduced its price target on Pfizer (NYSE:PFE) to $24 from $28, maintaining a Neutral rating as the firm highlights ...

Pfizer stock fell to the lowest closing price since 2012, putting its yield near 8%, after cautious comments from a UBS ...

These five well-known dividend stocks were beaten down in the recent selling but will remain attractive long after the tariff ...

UBS analyst Trung Huynh lowered the firm’s price target on Pfizer (PFE) to $24 from $28 and keeps a Neutral rating on the shares. The firm says ...

Pfizer’s blockbuster COVID era has officially left the chat, but the pharmaceutical giant is scripting a bold new chapter.

Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.

This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 ...

In what appears to be the near end of this year’s Idaho legislative session, Idaho Republican legislative leaders are backing ...

Over the past five years, Pfizer's stock has gone from boom to bust. The pandemic sent the stock price soaring as demand for ...